Pfizer's (PFE.US) $43 billion Seagen (SGEN.US) deal wins unconditional EU approval. As it was concluded by European lawmakers, deal wouldn't raise competition concerns or higher prices for oncology drugs.
Source: xStation5
Tesla preview: Narrative matters more than numbers
🔬 ASM International is driving the European tech and has released “stellar” forecasts🚀
Intel preview: Is there still room for gains?
UnitedHealth Group earnings: Healthy growth